Cardiac Diagnostics in the Age of Artificial Intelligence

Up Next

Cardiac Diagnostics in the Age of Artificial Intelligence

Average (ratings)
No ratings
Your rating
About the episode

Grant Neitzell subsequently provides a comprehensive review of innovation in ICMs, culminating in the LINQ™ series featuring AI-driven enhancements via AccuRhythm™, highlighting the diagnostic accuracy achieved.

Overview

In this on-demand version of the educational webinar, Dr Luca Santini (Rome, IT) and Prof Klaus Witte (Leeds, UK) join Alphons Vincent (Medtronic) and Grant Neitzell (architect of the Reveal LINQ system, Medtronic), to explore the critical importance of sensitivity and specificity in Insertable Cardiac Monitors (ICMs). The faculty consider how reducing false positives impacts sensitivity, why balancing these factors is essential, and what real-world data reveals about achieving clinical accuracy. The programme also highlights opportunities to streamline clinical workflows and minimise patient follow-ups.

 

Prof Witte discusses the impact on stroke patients, supported by findings from his recent poster presented at EHRA 2025, while Dr Santini presents real-life case studies, illustrating broader implications for various patient populations.

This programme is supported by:

Learning Objectives

  • The value of sensitivity in improved patient outcome
  • The value of specificity in improved clinical workflow
  • The impact of sensitivity on stroke and syncope patients
  • How not all ICMs are the same and how specificity and sensitivity, are differentiating the ICM market

This programme has particular educational value for:

  • Electrophysiologists
  • Cardiac physiologists
  • General cardiologists
  • Rhythmologists
  • Neurologists
  • All other healthcare professionals involved in arrhythmia management

More from this programme

Part 1

Welcome and Introduction

Alphons Vincent introduces the session’s agenda and learning objectives, with focus on how ICM sensitivity and specificity affect clinical outcomes, particularly in stroke and syncope patients, as well as highlighting that not all ICMs perform equally, with sensitivity driving accurate detection and specificity improving workflow by minimising false alerts.

Part 2

AI-driven Innovation in ICMs

Grant Neitzell provides a comprehensive review of innovation in ICMs, culminating in the LINQ™ series featuring AI-driven enhancements via AccuRhythm™, highlighting the diagnostic accuracy achieved.

Part 3

How ICM Sensitivity and Specificity Impact Clinical Decision Making – Klaus Witte

Prof Klaus Witte explores ICMs’ role for diagnosing unexplained syncope and cryptogenic stroke, offering superior diagnostic yield compared to conventional monitoring. He asserts that advances such as AccuRhythm™ AI improve specificity by reducing false positives – particularly for AF and pause events – while maintaining high sensitivity, which is critical for capturing clinically relevant arrhythmias.

Part 4

How ICM Sensitivity and Specificity Impact Clinical Decision Making – Luca Santini

Dr Luca Santini notes that ICMs are guideline-recommended for evaluating unexplained syncope and bradyarrhythmias, offering superior diagnostic yield in low-frequency or high-risk cases. He concludes that the current application of AI for loop recorders supports reducing false alerts, while maintaining high sensitivity and ensure patients’ safety.

Part 5

Panel Discussion and Summary

Alphons Vincent leads a panel discussion and audience Q&A, covering themes including clinical interpretation of AI-optimized ICM data, particularly around alert burden, AF thresholds, and false positives; diagnostic accuracy and sensitivity trade-offs, including concerns about missed or over-detected events; and practical integration into workflows, such as decision-making in unexplained syncope or silent AF cases.

Faculty Biographies

Grant Neitzell

Grant Neitzell

Grant Neitzell is a seasoned leader with over two decades of experience at Medtronic within the Cardiac Rhythm Management (CRM) and Cardiovascular Diagnostics (CDS) organisations. He currently serves as an Engineering Program Director. As the architect of the Reveal LINQ system, he has played a pivotal role in the evolution of insertable cardiac monitors (ICMs), drawing on his expertise in research and development, technical consulting, commercial strategy, and marketing.

Currently serving as the R&D Director of New Concepts for the Cardiovascular Diagnostics business, Grant continues to drive innovation in the ICM field. His contributions are reflected in over a dozen patents, four Medtronic Star of Excellence awards, and recognition as Medtronic’s Technical Contributor of the Year.

He holds a degree in Computer Engineering from the University of Minnesota.

View full profile